Patents by Inventor Henry C. Marsh

Henry C. Marsh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250059291
    Abstract: The invention provides CD27 agonists comprising a first component that is an anti-CD27 antibody, or antigen-binding fragment thereof, linked to a second component comprising one or more cross-linking moieties. At least one of the cross-linking moieties does not bind to an Fc receptor and the CD27 agonist stimulates T cell activity without the need for Fc receptor interaction. The cross-linking molecule(s) can be, for example, an anti-CD27, antibody, or antigen-binding fragment thereof, that can be the same or different than the first component. Alternatively, the cross-linking molecule(s) can be a CD27 ligand or a molecule (e.g., antibody) that binds a molecule on a cell such as a T cell, a tumor cell or a stromal cell. Pharmaceutical compositions comprising the CD27 agonists, and methods of using the CD27 agonists, are also provided.
    Type: Application
    Filed: May 17, 2024
    Publication date: February 20, 2025
    Inventors: Tibor KELER, Joel GOLDSTEIN, Lizhen HE, Henry C. MARSH, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Laura A. VITALE, Jenifer WIDGER
  • Publication number: 20230355673
    Abstract: The invention provides chimeric antigen receptors (CARs) that specifically bind to the T-cell immunoglobulin and mucin domain 1 (TIM-1) protein. The invention further relates to modified immune cells, e.g., T or NK cells, comprising such CARs, CAR-encoding nucleic acids, CAR-encoding vectors, and methods of making such compositions. The invention further relates to methods for therapeutic use of these CARs and modified immune cells for the treatment of a condition, disorder, or disease associated with cells expressing TIM-1 (e.g., cancer).
    Type: Application
    Filed: December 12, 2022
    Publication date: November 9, 2023
    Inventors: Terrance A. STADHEIM, Joana M. MURAD, Jake REDER, Henry C. MARSH, Li-Zhen HE, Tibor KELER
  • Patent number: 11541076
    Abstract: The invention provides chimeric antigen receptors (CARs) that specifically bind to the T-cell immunoglobulin and mucin domain 1 (TIM-1) protein. The invention further relates to modified immune cells, e.g., T or NK cells, comprising such CARs, CAR-encoding nucleic acids, CAR-encoding vectors, and methods of making such compositions. The invention further relates to methods for therapeutic use of these CARs and modified immune cells for the treatment of a condition, disorder, or disease associated with cells expressing TIM-1 (e.g., cancer).
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: January 3, 2023
    Assignees: CELDARA MEDICAL, LLC, CELLDEX THERAPEUTICS, INC.
    Inventors: Terrance A. Stadheim, Joana M. Murad, Jake Reder, Henry C. Marsh, Jr., Li-Zhen He, Tibor Keler
  • Publication number: 20220227877
    Abstract: Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: October 22, 2021
    Publication date: July 21, 2022
    Inventors: Tibor KELER, Henry C. MARSH, Lizhen HE, Laura A. VITALE, Lawrence J. THOMAS
  • Patent number: 11180566
    Abstract: Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: November 23, 2021
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Henry C. Marsh, Lizhen He, Laura A. Vitale, Lawrence J. Thomas
  • Publication number: 20190336534
    Abstract: The invention provides chimeric antigen receptors (CARs) that specifically bind to the T-cell immunoglobulin and mucin domain 1 (TIM-1) protein. The invention further relates to modified immune cells, e.g., T or NK cells, comprising such CARs, CAR-encoding nucleic acids, CAR-encoding vectors, and methods of making such compositions. The invention further relates to methods for therapeutic use of these CARs and modified immune cells for the treatment of a condition, disorder, or disease associated with cells expressing TIM-1 (e.g., cancer).
    Type: Application
    Filed: January 12, 2018
    Publication date: November 7, 2019
    Inventors: Terrance A. STADHEIM, Joana M. MURAD, Jake REDER, Henry C. MARSH, JR., Li-Zhen HE, Tibor KELER
  • Publication number: 20180044429
    Abstract: The invention provides CD27 agonists comprising a first component that is an anti-CD27 antibody, or antigen-binding fragment thereof, linked to a second component comprising one or more cross-linking moieties. At least one of the cross-linking moieties does not bind to an Fc receptor and the CD27 agonist stimulates T cell activity without the need for Fc receptor interaction. The cross-linking molecule(s) can be, for example, an anti-CD27, antibody, or antigen-binding fragment thereof, that can be the same or different than the first component. Alternatively, the cross-linking molecule(s) can be a CD27 ligand or a molecule (e.g., antibody) that binds a molecule on a cell such as a T cell, a tumor cell or a stromal cell. Pharmaceutical compositions comprising the CD27 agonists, and methods of using the CD27 agonists, are also provided.
    Type: Application
    Filed: March 9, 2016
    Publication date: February 15, 2018
    Inventors: Tibor KELER, Joel GOLDSTEIN, Lizhen HE, Henry C. MARSH, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Laura A. VITALE, Jenifer WIDGER
  • Patent number: 9649357
    Abstract: A method is disclosed for treating nephropathies involving undesired alternative pathway complement activation by administration of a complement inhibitory protein such as soluble complement receptor type I (sCR1).
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: May 16, 2017
    Assignees: CELLDEX THERAPEUTICS, INC., UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Richard J. H. Smith, Yuzhou Zhang, Henry C. Marsh
  • Publication number: 20160184392
    Abstract: A method is disclosed for treating nephropathies involving undesired alternative pathway complement activation by administration of a complement inhibitory protein such as soluble complement receptor type I (sCR1).
    Type: Application
    Filed: March 16, 2016
    Publication date: June 30, 2016
    Inventors: Richard J.H. SMITH, Yuzhou ZHANG, Henry C. MARSH
  • Patent number: 9295713
    Abstract: A method is disclosed for treating nephropathies involving undesired alternative pathway complement activation by administration of a complement inhibitory protein such as soluble complement receptor type I (sCR1).
    Type: Grant
    Filed: September 15, 2011
    Date of Patent: March 29, 2016
    Assignees: CELLDEX THERAPEUTICS, INC., UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Richard J. H. Smith, Yuzhou Zhang, Henry C. Marsh
  • Publication number: 20150337047
    Abstract: Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: July 2, 2015
    Publication date: November 26, 2015
    Inventors: Tibor KELER, Henry C. MARSH, Lizhen HE, Laura A. VITALE, Lawrence J. THOMAS
  • Patent number: 9169325
    Abstract: Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: October 27, 2015
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Henry C. Marsh, Lizhen He, Laura A. Vitale, Lawrence J. Thomas
  • Patent number: 8664176
    Abstract: A method is disclosed for treating diseases or disorders of the eye involving undesired neovascularization by administration of a complement inhibitory protein such as soluble complement receptor type I (sCR1). The present invention relates to the direct treatment of macular degeneration, particularly age-related macular degeneration (AMD), by administering a complement inhibitory protein intraocularly or systemically.
    Type: Grant
    Filed: October 19, 2007
    Date of Patent: March 4, 2014
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Henry C. Marsh, Lawrence Thomas, Hua Gao, Xiaoxi Qiao
  • Publication number: 20120213771
    Abstract: Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: October 19, 2011
    Publication date: August 23, 2012
    Applicant: CELLDEX THERAPEUTICS INC.
    Inventors: Tibor KELER, Henry C. MARSH, Lizhen HE, Laura A. VITALE, Lawrence J. THOMAS
  • Publication number: 20120071413
    Abstract: A method is disclosed for treating nephropathies involving undesired alternative pathway complement activation by administration of a complement inhibitory protein such as soluble complement receptor type I (sCR1).
    Type: Application
    Filed: September 15, 2011
    Publication date: March 22, 2012
    Inventors: Richard J. H. Smith, Yuzhou Zhang, Henry C. Marsh
  • Publication number: 20110274685
    Abstract: Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: April 13, 2011
    Publication date: November 10, 2011
    Applicant: CELLDEX THERAPEUTICS INC.
    Inventors: Tibor KELER, Henry C. MARSH, Lizhen HE, Laura A. VITALE, Lawrence J. THOMAS
  • Publication number: 20100130413
    Abstract: A method is disclosed for treating diseases or disorders of the eye involving undesired neovascularization by administration of a complement inhibitory protein such as soluble complement receptor type I (sCR1). The present invention relates to the direct treatment of macular degeneration, particularly age-related macular degeneration (AMD), by administering a complement inhibitory protein intraocularly or systemically.
    Type: Application
    Filed: October 19, 2007
    Publication date: May 27, 2010
    Inventors: Henry C. Marsh, Lawrence Thomas, Hua Gao, Xiaoxi Qiao
  • Patent number: 6316604
    Abstract: The present invention relates to the C3b/C4b receptor (CR1) gene and its encoded protein. The invention also relates to CR1 nucleic acid sequences and fragments thereof comprising 70 nucleotides and their encoded peptides or proteins comprising 24 amino acids. The invention further provides for the expression of the CR1 protein and fragments thereof. The genes and proteins of the invention have uses in diagnosis and therapy of disorders involving complement activity, and various immune system or inflammatory disorders. In specific embodiments of the present invention detailed in the examples sections infra, the cloning, nucleotide sequence, and deduced amino acid sequence of a full-length CR1 cDNA and fragments thereof are described. The expression of the CR1 protein and fragments thereof is also described. Also described is the expression of a secreted CR1 molecule lacking a transmembrane region.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 13, 2001
    Assignee: Avant Immunotherapeutics, Inc.
    Inventors: Douglas T. Fearon, Lloyd B. Klickstein, Winnie W. Wong, Gerald R. Carson, Michael F. Concino, Stephen H. Ip, Savvas C. Makrides, Henry C. Marsh, Jr.
  • Patent number: 6057131
    Abstract: Provided are methods of making preparations of recombinant soluble Complement Receptor type 1 (sCR1) defined with respect to the distribution of sCR1 glycoforms and therapeutic methods using them. The preparations are suitable for treatment of allograft or xenograft rejection, diseases involving inflammation or inappropriate complement activation, and thrombotic or shock state conditions. Preferred methods employ sCR1 glycoforms that are sialylated, have a pI of .ltoreq.5.1, or have a sialic acid: mannose molar ratio of .gtoreq.0.25.
    Type: Grant
    Filed: November 5, 1998
    Date of Patent: May 2, 2000
    Assignee: Avant Immunotherapeutics, Inc.
    Inventors: Henry C. Marsh, Jr., Richard A. G. Smith, Chang-Jing Grace Yeh, John Lifter, Anne Mary Freeman, Michael L. Gosselin
  • Patent number: 5981481
    Abstract: The present invention relates to the C3b/C4b receptor (CR1) gene and its encoded protein. The invention further provides for the expression of the CR1 protein and fragments thereof. The genes and proteins of the invention have uses in diagnosis and therapy of disorders involving complement activity, and various immune system or inflammatory disorders. In specific embodiments of the present invention detailed in the examples sections infra, the cloning, nucleotide sequence, and deduced amino acid sequence of a full-length CR1 cDNA and fragments thereof are described. The expression of the CR1 protein and fragments thereof is also described. Also described is the expression of a secreted CR1 molecule lacking a transmembrane region. The secreted CR1 molecule is shown to be useful in reducing damage caused by inflammation and in reducing myocardial infarct size and preventing reperfusion injury.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 9, 1999
    Assignees: The Johns Hopkins University, The Brigham & Women's Hospital, Avant Immunotherapeutics, Inc.
    Inventors: Douglas T. Fearon, Lloyd B. Klickstein, Winnie W. Wong, Gerald R. Carson, Michael F. Concino, Stephen H. Ip, Savvas C. Makrides, Henry C. Marsh, Jr.